Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease  Erik J. Schoon, Simona Bollani, Peter R. Mills, Eran Israeli, Dieter Felsenberg, Sverker Ljunghall, Tore Persson, Louise Haptén-White, Hans Graffner, Gabriele Bianchi Porro, Morten Vatn, Reinhold W. Stockbrügger  Clinical Gastroenterology and Hepatology  Volume 3, Issue 2, Pages 113-121 (February 2005) DOI: 10.1016/S1542-3565(04)00662-7 Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 1 Randomization and stratification of the patients included in the study and their clinical outcome. Clinical Gastroenterology and Hepatology 2005 3, 113-121DOI: (10.1016/S1542-3565(04)00662-7) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 2 Mean BMD expressed as T score (with standard error of the mean) during the 2-year study period in (A) corticosteroid-dependent (N = 90), (B) corticosteroid-free (N = 181), (C) corticosteroid-exposed (N = 83), and (D) corticosteroid-naive (N = 98) patients. Clinical Gastroenterology and Hepatology 2005 3, 113-121DOI: (10.1016/S1542-3565(04)00662-7) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 3 Mean CDAI (with standard error of the mean) during the 2-year study period in (A) corticosteroid-naive, (B) corticosteroid-exposed, and (C) corticosteroid-dependent patients. Clinical Gastroenterology and Hepatology 2005 3, 113-121DOI: (10.1016/S1542-3565(04)00662-7) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 4 Proportion of patients with normal ACTH test results at 0, 12, and 24 months in (A) corticosteroid-naive, (B) corticosteroid-exposed, and (C) corticosteroid-dependent patients. Clinical Gastroenterology and Hepatology 2005 3, 113-121DOI: (10.1016/S1542-3565(04)00662-7) Copyright © 2005 American Gastroenterological Association Terms and Conditions